Results of a phase IV, open-label safety study evaluating viloxazine ER (Qelbree®) administered with psychostimulants in pediatric (6-17 years) ADHD; morning vs. evening administration of...
Final results of a long-term, open-label extension of a pivotal phase 3 study leading to FDA-approval of viloxazine extended-release capsules (Qelbree®) in adults.
DR/ER-MPH is an evening-dosed delayed-release and extended-release methylphenidate that is released in the colon and provides a dose-dependent duration of effect for individuals aged ≥6y ...
Centanafadine (CTN) is a norepinephrine/dopamine/serotonin reuptake inhibitor being investigated for the treatment of attention-deficit/hyperactivity disorder (ADHD). Secondary efficacy o...
Centanafadine (CTN) is a novel norepinephrine/dopamine/serotonin reuptake inhibitor in development for attention-deficit/hyperactivity disorder (ADHD). Long-term (52 weeks) safety and exp...
Cingulate has conducted a Phase 3 randomized, placebo controlled efficacy and safety study along with onset and duration in 21 adults with ADHD using CTx-1301 in a laboratory classroom se...
In a pivotal study, d-ATS applied to the hip met primary and secondary efficacy endpoints for ADHD in children and adolescents. In this open-label crossover study, healthy adults were ran...
Centanafadine is a norepinephrine/dopamine/serotonin reuptake inhibitor in development for treatment of attention-deficit/hyperactivity disorder (ADHD). The effect of centanafadine on car...
Abstract: Viloxazine ER (viloxazine extended-release capsules, Qelbree®) is a novel, nonstimulant, FDA-approved treatment for adults and children (≥6 yrs) with ADHD. Viloxazine ER inhibit...
Abstract: Aim: To evaluate changes in attention-deficit hyperactivity disorder (ADHD) severity in children (aged 6-12 years) posttreatment with serdexmethylphenidate/dexmethylphenidate (S...
Abstract: Aim: To quantify the value of Azstarys (serdexmethylphenidate/dexmethylphenidate) for patients with attention-deficit hyperactivity disorder (ADHD) with real-world data from the...
Abstract: Viloxazine ER is a novel, nonstimulant, FDA-approved treatment for ADHD in children and adults (≥ 6 years). Viloxazine ER effects on executive function (EF) deficits were evalua...
Abstract: Viloxazine ER (Qelbree®) is a novel, nonstimulant, FDA-approved treatment for ADHD in pediatric patients (≥6 years) and adults. The efficacy of viloxazine ER was evaluated in 4 ...
Abstract: Purpose: Immediate-release methylphenidate (IR MPH) is sometimes dosed in the afternoon to extend the duration of effect of a morning-dosed extended-release (ER) MPH for attenti...
Abstract: Background:
In a pivotal study, the dextroamphetamine transdermal system (d-ATS) met primary and secondary efficacy endpoints for ADHD in children and adolescents. This post-hoc...
Abstract: Aim: To determine sleep behavior during serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) treatment in children with attention-deficit hyperactivity disorder (ADHD).
Method...
Abstract: Purpose: Emotional lability (EL) is commonly seen in individuals with attention-deficit/hyperactivity disorder (ADHD). A post hoc analysis found that DR/ER-MPH (formerly HLD200)...
Celebrating 35 years of empowering the highest standard in mental healthcare, Psych Congress serves as a unique, integrated forum to connect members of the entire mental health team—bringing together psychiatrists, nurse practitioners, physician assistants, psychologists, primary care physicians, and other mental health professionals for 4 days of practical education to improve patient care.